AJINOMOTO BIOPHARMA https://validator.w3.org/feed/docs/rss2.html NJ Bio, Inc. と味の素バイオファーマサービス、抗体薬物複合体（ADC）開発支援強化に向けた協業を開始 Presentation at PEPTALK PEPTALK 発表のお知らせ 味の素バイオファーマサービスとOlon、ペプチド・タンパク質大量生産を革新する戦略的提携 Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody–Drug Conjugate Development 味の素バイオファーマサービス、AJICAP<span class="registered-mark" style="vertical-align: bottom;">®</span>技術に関する論文で「Best ADC Preclinical Publication 2024」受賞 ～2025年World ADC Awards Ajinomoto Co., Inc. Enters Licensing Agreement with Astellas Pharma Inc. for Biopharmaceutical Development and Manufacturing Technology 味の素㈱、バイオ医薬品に関する開発・製造技術で アステラス製薬とライセンス契約を締結 CORYNEX JP-CORYNEX AJICAP<span class="registered-mark">®</span> Second Generation was awarded in World ADC conference ! AJICAP<span class="registered-mark">®</span> 第二世代が受賞 Best ADC Preclinical Publication 2023 味の素㈱と㈱リボミックの共同研究において 核酸アプタマーの薬物動態延長に成功 ～抗体薬物複合体製造技術AJICAP<span class="registered-mark">®</span>が抗体医薬の薬効向上に貢献～ Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. -AJICAP<span class="registered-mark">®</span> Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs- Ajinomoto Bio-Pharma Services Wins “Best ADC Preclinical Publication 2024” Award for AJICAP<span class="registered-mark" style="vertical-align: bottom;">®</span> Technology at 2025 World ADC Awards Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics 第26回 インターフェックス Week 東京出展・発表のお知らせ Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing CPHI Frankfurt 2025 出展のお知らせ Exhibition at CPHI Frankfurt 2025 Exhibition and Presentation at Biologics US 2025 Biologics US 2025 出展・発表のお知らせ BioJapan 2025 出展のお知らせ Exhibition at BioJapan 2025 JP-CONTACT CONTACT インターフェックス Week 東京2025出展・発表のお知らせ NextGen Biomed 2025 出展・発表のお知らせ 味の素㈱、米国医薬品無菌充填受託会社の 味の素アルテア社の全株式を売却予定※ ～ヘルスケア領域におけるバイオファーマサービスの高付加価値化を加速～ We’re attending at TIDES ASIA 2025 Ajinomoto Co., Inc. to Sell its Entire Equity Stake in Ajinomoto Althea, a US-based Aseptic Fill/Finish CDMO CPHI Japan 2025 出展・発表のお知らせ Exhibition and Presentation at CPHI Japan 2025 World ADC London 2025 出展・発表のお知らせ We’re attending at World ADC London 2025 We’re attending at NextGen Biomed 2025 PEPTALK 2025 出展・発表のお知らせ Exhibition and Presentation at PEPTALK 2025 We’re attending at TIDES EUROPE 2024 TIDES EUROPE 2024 出展・発表のお知らせ TIDES ASIA 2025 出展・発表のお知らせ Exhibition and Presentation at BioJapan 2024 BioJapan 2024 出展・発表のお知らせ AJICAP CPHI Milan 2024 出展のお知らせ Exhibition at CPHI Milan 2024 JP-AJICAP Exhibition and Presentation at 26th INTERPHEX Week Tokyo Exhibition and Presentation at INTERPHEX Week Tokyo 2025